AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (sleeve gastrectomy)
Number of subjects: 500
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (gastric bypass)
Number of subjects: 500
Study 24374423 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed
Number of subjects: 500
Study 24374423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 500
Study 24374547 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic meshes
Number of subjects: 40
Study 24374856 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg abiraterone acetate (tablet)
Number of subjects: 16
Study 24374856 — intervention group
Group type: COMPARATOR
Intervention: 125 mg and 2,000 mg abiraterone acetate (suspension)
Number of subjects: 16
Study 24375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone (BioT)
Number of subjects: 598
Study 24375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist and subcutaneous adipose tissue (SAT)
Number of subjects: 598
Study 24375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist
Number of subjects: 598
Study 24375324 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 598
Study 24376516 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-lavaging device (Delphi Screener™) for cytology and HPV testing
Number of subjects: 198
Study 24376516 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-lavaging device (Delphi Screener™) for HPV testing
Number of subjects: 198
Study 24376864 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Aggregatibacter actinomycetemcomitans (Aa)
Number of subjects: 30
Study 24376864 — intervention group
Group type: COMPARATOR
Intervention: Aa-non-detected sites
Number of subjects: 30
Study 24376864 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood samples
Number of subjects: 30
Study 24376864 — intervention group
Group type: EXPERIMENTAL
Intervention: E.coli LPS stimulation of peripheral blood cells from Aa-detected sites
Number of subjects: 30
Study 24376864 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters and serum LPS levels
Number of subjects: 30
Study 24377099 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine in Montanide adjuvant
Number of subjects: 0
Study 24377099 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine in Montanide adjuvant with GM-CSF
Number of subjects: 0
Study 24378417 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day by mouth for up to 12 months, with possible dose escalation to 600 mg/day at 3 months if stable.
Number of subjects: 30
Study 24378877 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS+HIPEC (laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy)
Number of subjects: 84
Study 24378877 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC treatment with cisplatin at 75 mg/m(2) or oxaliplatin 460 mg/m(2)
Number of subjects: 84
Study 24378877 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS+HIPEC
Number of subjects: 84
Study 24379526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with secondary ERMs after PDR
Number of subjects: 17
Study 24379526 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with idiopathic ERMs)
Number of subjects: 17
Study 24379928 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on extended release nicotinic acid (ER-NA)/laropiprant (LRPT)
Number of subjects: 100
Study 24379928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin monotherapy (40 mg/d)
Number of subjects: 100
Study 24379928 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on micronised fenofibrate
Number of subjects: 100
Study 24380752 — intervention group
Group type: EXPERIMENTAL
Intervention: drug-targeting nebulization
Number of subjects: 0
Study 24381190 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of salbutamol
Number of subjects: 405
Study 24381190 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ENO) measurement
Number of subjects: 405
Study 24381190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator FEV1
Number of subjects: 405
Study 24381226 — intervention group
Group type: EXPERIMENTAL
Intervention: Otlertuzumab administered intravenously, ranging from 0.03 to 20 mg/kg in dose-escalation phase and 10 to 30 mg/kg in dose-expansion phase, weekly for up to 8 weeks followed by 1 dose per month for 4 months.
Number of subjects: 83
Study 24381226 — intervention group
Group type: EXPERIMENTAL
Intervention: Otlertuzumab
Number of subjects: 83
Study 24381750 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat measurement by ultrasound
Number of subjects: 165
Study 24382963 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 14
Study 24382963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema in or near SNRPF (rs7957346)
Number of subjects: 7914
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema in or near PPT2 (rs10947233)
Number of subjects: 7914
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near MAN2B1 (rs10411619) among Hispanics
Number of subjects: 7914
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near DHX15 (rs7698250) among Chinese
Number of subjects: 7914
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for upper-lower lobe ratio near MGAT5B (rs7221059) among Chinese
Number of subjects: 7914
Study 24383474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis for percent emphysema near MAN1C1 (rs12130495) among African Americans
Number of subjects: 7914
Study 24383664 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (220 mg per capsule, 2 capsules per day for 3 months)
Number of subjects: 60
Study 24383664 — intervention group
Group type: COMPARATOR
Intervention: Fertile controls (no treatment)
Number of subjects: 60
Study 24383821 — intervention group
Group type: EXPERIMENTAL
Intervention: AposTherapy (non-invasive biomechanical foot-worn device)
Number of subjects: 58
Study 24383844 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful cytogenetic analysis (UC)
Number of subjects: 1497
Study 24383844 — intervention group
Group type: COMPARATOR
Intervention: Successful cytogenetic analysis
Number of subjects: 1497
Study 24384108 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day adhesive patch monitor
Number of subjects: 146
Study 24384108 — intervention group
Group type: COMPARATOR
Intervention: 24-hour Holter monitor
Number of subjects: 146
Study 24384290 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacute ST
Number of subjects: 46
Study 24384290 — intervention group
Group type: EXPERIMENTAL
Intervention: Late/very late ST
Number of subjects: 46
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 197
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 197
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II score
Number of subjects: 197
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: MODS score
Number of subjects: 197
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying lung diseases, serum albumin, serum creatinine, number of organ failures
Number of subjects: 197
Study 24384417 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II and MODS systems
Number of subjects: 197
Study 24384609 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1,500 μg
Number of subjects: 906
Study 24384609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 24384609 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1,500 μg (in cases with high baseline clinical score ≥13)
Number of subjects: 906
Study 24384609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in cases with high baseline clinical score ≥13)
Number of subjects: 906
Study 24385027 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid + Vitamin B6 (CTG)
Number of subjects: 75
Study 24385027 — intervention group
Group type: COMPARATOR
Intervention: Linezolid only (LTG)
Number of subjects: 75
Study 24385474 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour training course (4 meetings of 3 hours each in 1 month) for community health workers
Number of subjects: 65
Study 24385474 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour training course
Number of subjects: 65
Study 24385516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (B6) administered orally starting at 5 mg/kg body weight per day, increasing by 5 mg/kg every 6 weeks up to 20 mg/kg per day at week 24.
Number of subjects: 12
Study 24386229 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture introduction
Number of subjects: 258
Study 24386300 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 400/12 µg twice a day for 4 weeks
Number of subjects: 37
Study 24386300 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 37
Study 24386357 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 1060
Study 24386357 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 1060
Study 24387695 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 45 mg QOD with carboplatin (AUC 6.0) and paclitaxel 200 mg/m2
Number of subjects: 72
Study 24387695 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 200 mg Q3W with docetaxel 75 mg/m2
Number of subjects: 72
Study 24387695 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 135 mg QW with erlotinib 100 or 150 mg daily
Number of subjects: 72
Study 24387695 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (various doses)
Number of subjects: 72
Study 24388030 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic manipulation targeting newly identified cellular and molecular targets in liver regeneration.
Number of subjects: 0
Study 24388030 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical models of liver injury.
Number of subjects: 0
Study 24388161 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 4-8 weeks
Number of subjects: 539
Study 24388161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who returned for follow-up
Number of subjects: 539
Study 24388161 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not return for follow-up
Number of subjects: 539
Study 24388292 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (action plan)
Number of subjects: 270
Study 24388292 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based intervention (persuasive communication)
Number of subjects: 270
Study 24388292 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based IME methodology
Number of subjects: 270
Study 24388332 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (UCB) cells, up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose
Number of subjects: 23
Study 24388332 — intervention group
Group type: COMPARATOR
Intervention: Cooled infants without available cells (control group)
Number of subjects: 23
Study 24388695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel (LNG) taken shortly after sex
Number of subjects: 72
Study 24389297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg administered subcutaneously at baseline, week 4, and week 16
Number of subjects: 20
Study 24389906 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA concentration at C4
Number of subjects: 50
Study 24389906 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC concentration at C0 or C2
Number of subjects: 50
Study 24389906 — intervention group
Group type: EXPERIMENTAL
Intervention: C0 for TAC monitoring
Number of subjects: 50
Study 24389906 — intervention group
Group type: EXPERIMENTAL
Intervention: C0 with CsA
Number of subjects: 50
Study 24392226 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 0
Study 24392948 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0
Study 24393402 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (graded physical stress test)
Number of subjects: 87
Study 24393402 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no exercise intervention)
Number of subjects: 87
Study 24393402 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients (exercise intervention)
Number of subjects: 87
Study 24393402 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy female individuals (exercise intervention)
Number of subjects: 87
Study 24393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 9161
Study 24393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects aged <60 years
Number of subjects: 9161
Study 24393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 9161
Study 24393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fasting glucose levels (6.39±0.49 vs 6.24±0.43 mmol/L)
Number of subjects: 9161
Study 24393475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall IFG subjects
Number of subjects: 9161
Study 24394678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending sexually explicit messages and/or pictures)
Number of subjects: 322
Study 24394678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending photos)
Number of subjects: 322
Study 24394678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexting behavior (sending text messages)
Number of subjects: 322
Study 24394678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexting behavior (both photo and text messages)
Number of subjects: 322
Study 24395025 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of TIV and PCV13
Number of subjects: 530
Study 24395025 — intervention group
Group type: COMPARATOR
Intervention: TIV alone
Number of subjects: 530
Study 24395025 — intervention group
Group type: COMPARATOR
Intervention: PCV13 alone
Number of subjects: 530
Study 24396131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dystonia group (7 participants)
Number of subjects: 16
Study 24396131 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 healthy volunteers)
Number of subjects: 16
Study 24396625 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir-based regimen
Number of subjects: 32
Study 24397612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3CL configuration (3rd nail from lateral)
Number of subjects: 17
Study 24397612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3CM configuration (3rd nail from medial)
Number of subjects: 17
Study 24397612 — intervention group
Group type: COMPARATOR
Intervention: 2C configuration (2C-shaped nails, 2 × 3.5 mm)
Number of subjects: 17
Study 24397612 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ESIN (3CL or 3CM)
Number of subjects: 17
Study 24398064 — intervention group
Group type: EXPERIMENTAL
Intervention: CC2 (PillCam Colon2)
Number of subjects: 50
Study 24398064 — intervention group
Group type: COMPARATOR
Intervention: CTC (Computed Tomographic Colonography)
Number of subjects: 50
Study 24398064 — intervention group
Group type: COMPARATOR
Intervention: Preference for CC2 over CTC
Number of subjects: 50
Study 24398331 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-sparing treatments
Number of subjects: 150
Study 24398331 — intervention group
Group type: EXPERIMENTAL
Intervention: FAS mutations
Number of subjects: 150
Study 24398331 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum vitamin B12
Number of subjects: 150
Study 24398331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoma risk
Number of subjects: 150
Study 24398331 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 150
Study 24399330 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hormone therapy
Number of subjects: 0
Study 24399330 — intervention group
Group type: COMPARATOR
Intervention: Placebo hormone therapy
Number of subjects: 0
Study 24400847 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (mean daily doses: bisoprolol 5.5 mg, metoprolol 73.7 mg)
Number of subjects: 399
Study 24400912 — intervention group
Group type: EXPERIMENTAL
Intervention: Set-valued dynamic treatment regimes (DTRs) that accommodate competing outcomes.
Number of subjects: 0
Study 24400912 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact enumeration algorithm for constructing DTRs.
Number of subjects: 0
Study 24401226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose in isocaloric exchange for other carbohydrate (n=290)
Number of subjects: 323
Study 24401226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose providing excess energy (hypercaloric trials, n=33)
Number of subjects: 323
Study 24401718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2005 (HEI-2005)
Number of subjects: 494967
Study 24401718 — intervention group
Group type: EXPERIMENTAL
Intervention: alternate Mediterranean Diet Score (aMED)
Number of subjects: 494967
Study 24401885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal advancement flap combined with platelet-rich plasma
Number of subjects: 25
Study 24401885 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 24402314 — intervention group
Group type: COMPARATOR
Intervention: Emergency endoscopic sclerotherapy (EEST)
Number of subjects: 365
Study 24402314 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 365
Study 24402314 — intervention group
Group type: COMPARATOR
Intervention: Transjugular intrahepatic portal-systemic shunt (TIPS)
Number of subjects: 365
Study 24402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Smell Identification Test (B-SIT)
Number of subjects: 445
Study 24402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography and nasal endoscopy
Number of subjects: 445
Study 24402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyposis
Number of subjects: 445
Study 24402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalcitrant disease and aspirin intolerance
Number of subjects: 445
Study 24402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific QOL measures (Rhinosinusitis Disability Index and Sinonasal Outcome Test)
Number of subjects: 445
Study 24402982 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART) - 2 sessions
Number of subjects: 1
Study 24405647 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor parotid anterior approach
Number of subjects: 60
Study 24405647 — intervention group
Group type: COMPARATOR
Intervention: Retromandibular approach
Number of subjects: 60
Study 24406779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of the superotemporal retinal artery
Number of subjects: 49
Study 24406779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of arteriovenous nicking (AVN)
Number of subjects: 49
Study 24406779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of focal arteriolar narrowing (FAN)
Number of subjects: 49
Study 24407191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.d. and irinotecan 180 mg m(-2) every 2 weeks (Phase II)
Number of subjects: 64
Study 24408338 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with the Speech-language pathologist (SLP)
Number of subjects: 21
Study 24408338 — intervention group
Group type: COMPARATOR
Intervention: Interaction with the mother
Number of subjects: 21
Study 24408395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg BID
Number of subjects: 4
Study 24408516 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine)
Number of subjects: 247
Study 24408973 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum intensity (MI) of optical coherence tomography (OCT) A-scans
Number of subjects: 24
Study 24410126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA (1 mM) and IL13-PE (0.125 μg/ml)
Number of subjects: 4
Study 24410126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA (5 mM) and IL13-PE (0.25 μg/ml)
Number of subjects: 4
Study 24410943 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily for 4 weeks
Number of subjects: 17
Study 24411228 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week schedule of radiotherapy with oral capecitabine (1650 mg/m²/day)
Number of subjects: 80
Study 24412048 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSavin (1·9×10(7) TU)
Number of subjects: 15
Study 24412048 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSavin (4·0×10(7) TU)
Number of subjects: 15
Study 24412048 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSavin (1×10(8) TU)
Number of subjects: 15
Study 24412141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing disease (CD)
Number of subjects: 124
Study 24412141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone-independent CS (AICS)
Number of subjects: 124
Study 24412141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing syndrome (CS)
Number of subjects: 124
Study 24412141 — intervention group
Group type: COMPARATOR
Intervention: Children with advanced BA
Number of subjects: 124
Study 24412141 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Cushing disease (CD) post-surgery
Number of subjects: 124
Study 24412228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily until disease progression
Number of subjects: 44
Study 24412228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44
Study 24412444 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate
Number of subjects: 5000
Study 24412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction PET (PI-PET) scan
Number of subjects: 202
Study 24413185 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based intervention for physical activity in cardiac rehabilitation
Number of subjects: 11